14 Nov 2013 --- New research demonstrates the ability of ResistAid, Lonza’s proprietary, arabinogalactan-based immune support ingredient, to increase the antibody response in healthy adults after exposure to the Tetanus vaccine. Conducted at a dosage of 1.5 g/day, the study finds the efficacy of ResistAid at a significantly lower dosage, as compared to the 4.5 g/day that was previously found to be effective.